$100+ Billion spent on myriad of acquisitions across Pharma and Biotech industries in H1 2018
Lloyd Price
JULY 5, 2018
The move provided Celgene with a therapy that could challenge rival drugmakers Novartis and Incyte in the myelofibrosis space. pharma giant had partnered with Novartis on the business division. The deal for Impact wasn’t the only one undertaken by Celgene. The Swiss company held a 36.5 percent interest in the business.
40 
Let's personalize your content